Kenji Katsumata, Tetsuo Sumi, Tatehiko Wada, Yasuharu Mori, Masayuki Hisada, Hideaki Kawakita, Masanori Enomoto, Shoji Suzuki, Daisuke Matsuda, Akihiko Tsuchida and Tatsuya Aoki

Third Department of Surgery, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku, Tokyo, Japan 160-0023.

Abstract

Objective: Oxaliplatin, a key part of the standard regimen for colorectal cancer in Western countries, has become available in Japan. In a hemodialysis patient with cecal cancer, we investigated the effi cacy, safety, pharmacokinetics, and dialysability of oxaliplatin.

Methods: A 65-year-old man who had cecal cancer was treated with oxaliplatin (40 mg/m2) and l-leucovorin(l-LV) (200 mg/m2), which were administered simultaneously over 120 min via the side and main arms of a Y-tube, respectively. Then 5-FU (400 mg/m2) was administered rapidly via the side tube, followed by 5-FU (2,000 mg/m2) over 46 hours via the main tube. The patient had chronic renal failure due to diabetic nephropathy and hemodialysis was performed 3 times a week. Blood samples were collected from the dialyzer before and after each hemodialysis session to examine platinum clearance.

Results: The patient received 3 courses of oxaliplatin before he died of cancer. During hemodialysis, the platinum level fell from 0.32 μg/mL to 0.15 μg/mL.

Conclusion: Since patients with renal failure have various associated disorders and oxaliplatin has a long half-life, it is necessary to obtain more pharmacokinetic data to investigate its accumulation and dialysability during long-term treatment. Such data will assist in treating the rapidly increasing number of hemodialysis patients with colorectal cancer.